HALOZYME REPORTS THIRD QUARTER 2026 RESULTS AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE

Halozyme reported Q3 2026 revenue of $493.0 million, up 39% year over year, including royalty revenue of $341.0 million, up 44%; diluted GAAP EPS rose to $2.01 from $1.43. The company raised 2026 guidance to $1.860–$1.925 billion in revenue, $1.240–$1.290 billion in adjusted EBITDA, and $8.75–$9.05 in non-GAAP diluted EPS. It also cited a Dutch court injunction barring Merck’s Keytruda Qlex launch in eight named European markets over infringement of one Halozyme patent, and reported $400 million in 2026 share repurchases.

Analysis

The key underwriting question is whether royalty growth can keep compounding after the current launch cohort matures—not whether this quarter was strong. On reported year-to-date royalties, the 2026 outlook implies roughly $346–366m in Q4, only about $5–25m above Q3. That points to limited sequential lift embedded in the raised outlook, despite high full-year growth, and makes the next quarter’s partner-product sell-through more informative than the headline growth rate. Growth is also concentrated in a handful of partnered products, so slower uptake or reimbursement friction at a major franchise can transmit directly to HALO.

The Dutch ruling offers potential bargaining leverage and could delay Merck’s SC formulation in the specified European markets, but it is not a global Keytruda franchise impairment: appeals or a stay could reverse the restriction, and patients may remain on IV treatment. A favorable ruling may strengthen Halozyme’s IP position; it does not by itself establish incremental royalties or cash receipts. Separately, the large convertible financing and buybacks create a capital-allocation tradeoff: cash supports flexibility, while debt service and potential dilution temper the per-share benefit of operating growth. Non-GAAP EPS/EBITDA also exclude meaningful recurring amortization and other adjustments, so track GAAP conversion.

Contrarian read: the business outlook is robust, but the raise itself is modest relative to the growth narrative, and the implied Q4 royalty cadence does not signal a fresh step-change. The call’s detail on partner demand, product mix, and the injunction’s enforceability should determine whether to add exposure rather than extrapolating the annual growth rate.

Key Decisions for Investors

• HALO: avoid chasing a sharp opening move; consider scaling into a long on post-call weakness only if management confirms partner sell-through and the Q4 royalty run rate remains consistent with guidance. Falsify the thesis on a guidance cut or two consecutive quarters of flat-to-lower royalties.
• Set a near-term event watch on the Dutch injunction: verify appeal and stay status and whether the restriction is being enforced in each named market. Treat any HALO royalty upside as contingent until commercial impact is disclosed; do not short MRK solely on this ruling.
• Monitor the next reporting cycle for royalties by major product/partner, guidance-to-GAAP reconciliation, and convertible-note dilution/cash deployment. If growth proves concentrated while sequential royalties stall, reduce HALO exposure rather than relying on the long-duration platform narrative.